Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 7 5 versus ADDERALL XR 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 7 5 versus ADDERALL XR 25.
ADDERALL 7.5 vs ADDERALL XR 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADDERALL 7.5 is a combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action involves blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, as well as increasing their release into the extraneuronal space. This leads to increased levels of these neurotransmitters in the synaptic cleft, enhancing stimulation of postsynaptic receptors.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
5-20 mg orally 1-3 times daily; immediate-release tablets administered upon awakening and at 4-6 hour intervals as needed; extended-release capsules administered once daily upon awakening; maximum total daily dose 40 mg.
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
None Documented
None Documented
The terminal elimination half-life of amphetamine is approximately 10-13 hours in adults, but can vary based on urinary pH (alkaline urine prolongs half-life up to 20 hours; acidic urine reduces it to 7-8 hours). In children, half-life is slightly shorter (6-8 hours). Clinical context: Steady-state is achieved within 2-3 days.
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites (including deaminated and hydroxylated products). Fecal excretion is negligible (<5%).
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant